论文部分内容阅读
美国圣路易斯消息:15～20个美国和加拿大医学中心即将用药物SR-2508作66次主要临床试验。据说此药能使放疗抗癌效力增加一倍。华盛顿大学附属医学院放疗专家Todd Wasserman称,当药物进入肿瘤后,能够保证辐射破坏瘤细胞,使瘤细胞无法恢复。他领导的肿瘤放射治疗小组将采用SR-2508对癌瘤病人进行试验。一些实验和一项早期临床试验表明,SR-2508增强放疗和穿透肿瘤的能力比过去试验过的放射增敏剂更均匀,无主要副作用。用量是其它放射增敏剂的3倍。按给药的途径及机体对药物的代谢,每周5
US St. Louis News: 15 to 20 US and Canadian medical centers are about to use drug SR-2508 for 66 major clinical trials. It is said that this medicine can double the anticancer effect of radiotherapy. Todd Wasserman, an expert in radiation therapy at the University of Washington School of Medicine, said that when the drug enters the tumor, it can ensure that the radiation destroys the tumor cells and the tumor cells cannot recover. The cancer radiotherapy team he led will use SR-2508 to test cancer patients. Several experiments and one early clinical trial showed that SR-2508 has more uniform radiotherapy and tumor penetration than the radiosensitizers tested in the past, with no major side effects. The dosage is 3 times that of other radiosensitizers. According to the route of administration and the body’s metabolism of the drug, 5 per week